Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belzutifan - Merck & Co

Next Previous
Drug Profile

Belzutifan - Merck & Co

Alternative Names: MK 6482; PT-2977; WELIREG; WELIREGTM

Latest Information Update: 23 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Peloton Therapeutics
  • Developer Eisai Inc; Merck & Co; Merck Sharp & Dohme; Peloton Therapeutics
  • Class Antineoplastics; Benzonitrile; Fluorobenzenes; Indenes; Small molecules; Sulfones
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Von Hippel-Lindau disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Paraganglioma; Phaeochromocytoma; Renal cell carcinoma; Von Hippel-Lindau disease
  • Preregistration Neuroendocrine tumours
  • Phase III Solid tumours
  • Phase II Gastrointestinal stromal tumours; HER2 negative breast cancer
  • Phase I/II Prostate cancer
  • Discontinued Iron overload

Most Recent Events

  • 21 Oct 2026 Phase-II clinical trials in Solid tumours (In adolescents, Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Denmark, Spain, South Korea, Belgium, USA (PO) (NCT07700758)
  • 25 Sep 2026 Registered for Renal cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA (PO)
  • 25 Sep 2026 Adverse events data from a phase III LITESPARK-011 trial in Renal cell carcinoma released by Merck & Co

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top